Will Aphria (NYSE:APHA) price increase in May 2021?

While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to go over Aphria Inc. We will check why this entity may not get much respect from investors given the current market uncertainty. Is the stock valuation sustainable? Here I will cover a perspective on valuation of Aphria to give you a better outlook on taking a position in this stock.
Published over a year ago
View all stories for Aphria | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Michael Smolkin

This firm currently holds 434.04 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the entity is not taking enough advantage from borrowing. The company has a current ratio of 2.31, suggesting that it is liquid enough and is able to pay its financial obligations when due.
Our trade advice tool can cross-verify current analyst consensus on Aphria Inc and to analyze the company potential to grow in the current economic cycle.

Aphria Inc Investment Alerts

Aphria investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Aphria Inc performance across your portfolios.Please check all investment alerts for Aphria

Aphria Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Aphria value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aphria competition to find correlations between indicators driving the intrinsic value of Aphria.

What is the case for Aphria Investors

Aphria Inc reported the previous year's revenue of 477.1 M. Net Loss for the year was (173.48 M) with profit before overhead, payroll, taxes, and interest of 190.97 M.
 2018 2019 2020 2021 (projected)
Revenues USD176.95 M393.72 M452.78 M488.53 M
Revenues237.11 M543.34 M624.84 M674.17 M

Margins Breakdown

Aphria profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Aphria itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Aphria profit margins.
EBITDA Margin(0.008313)
Gross Margin0.45
Profit Margin(0.14)
Aphria Average Equity is increasing over the last 5 years. The current value of Aphria Average Equity is 1,819,379,153. Also, Aphria Earnings before Tax is somewhat stable at the moment.

Aphria may start a correction in May

Current downside deviation is at 8.58. Aphria Inc is displaying above-average volatility over the selected time horizon. Investors should scrutinize Aphria Inc independently to ensure intended market timing strategies are aligned with expectations about Aphria volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Aphria's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Aphria's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Aphria Inc

Whereas some firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Aphria may offer a potential longer-term growth to investors. While some in two-three weeks oriented investors may not share our view, we believe it may not be a good time to buy new shares of Aphria.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Aphria Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com